Short Term Plays

[jkids210]

Check out SOIGF.PK

[I Love Roth Iras]

TVIX the stock to own when the markets go down. In @ $55.40.

[I Love Roth Iras]

TVIX - buy the dips heading into possible Greek default......Out of cash by Sept 30.

[I Love Roth Iras]

TDCP - great technology w/ patents - no debt - just announced they will not reverse split....get in now!

[I Love Roth Iras]

Immu - coverage initiated....good things coming...

[I Love Roth Iras]

ccme....today...will gap down at open, short into the spike back up.

[I Love Roth Iras]

TDCP........

[I Love Roth Iras]

TDCP........

[taraniterror]

NCEN BABY ~

[taraniterror]

TIE ~ continues to surge forward

[taraniterror]

SSCCQ ! wHOA ~

[jkids210]

MRNA- RNAi company in its development stage. New management has restructured the company. Leading RNAi company with a broad portfolio of patents.

BOTHELL, WA--(MARKET WIRE)--May 14, 2009 -- MDRNA, Inc. (NasdaqGM:MRNA - News) today reported financial results for the first quarter ended March 31, 2009.

Related Quotes
Symbol Price Change
MRNA 1.45 +0.30


{"s" : "mrna","k" : "c10,l10,p20,t10","o" : "","j" : ""} "The first quarter of 2009 was a period of significant accomplishment for the Company," stated J. Michael French, President and Chief Executive Officer. "With the sale of our intranasal contract manufacturing operations in Hauppauge, N.Y. on March 31st, we completed our transition from a clinical stage delivery company to a pre-clinical RNAi drug discovery company, having reduced or eliminated all of our legacy liabilities within the last nine months. In addition, during the quarter, we generated over $12 million in revenue solely from our RNAi technologies. More importantly, we believe the agreements with Roche and Novartis have validated the key aspects of our RNAi drug discovery engine: siRNA constructs and siRNA delivery. We expect to leverage the validation of our platform into multiple target and therapeutic-based research and development collaborations with additional pharmaceutical companies. Having completed our transition to an RNAi drug discovery company, we feel we have emerged as a true leader in the field."

Revenue for the three months ended March 31, 2009 was $14.2 million, compared to $1.3 million for the quarter ended March 31, 2008. The 2008 period included $0.7 million in license and research fee revenue, $0.5 million in Nascobal® product sales and $0.1 million in government grants. Revenue in 2009 primarily included upfront licensing fees of $7.25 million from Novartis, upfront licensing fees of $5.0 million from Roche, recognition of $1.0 million in milestone revenue from Amylin Pharmaceuticals, Inc. related to the amendment to our 2006 License Agreement and recognition of the remaining $0.7 million of deferred revenue from the $2.0 million payment received in 2005 from QOL due to the Asset Purchase Agreement with Par Pharmaceutical Companies, Inc. entered into during the first quarter 2009.

Net income for the current quarter was approximately $7.3 million or $0.23 per share, compared to a net loss of $16.5 million or $0.63 loss per share for the prior year quarter. This positive net income, compared to the loss in the 2008 period, reflects in large part revenue from licensing transactions in the RNA interference space enabled by our broad RNAi intellectual property estate and drug discovery platform. These license agreements, as well as target and therapeutic-based research and development collaborations, represent the types of periodic transactions contemplated as part of our business strategy.

Research and development ("R&D") expenses for the current quarter decreased $6.7 million to $4.2 million compared to the prior year quarter. In the current quarter, the decrease in our R&D expenses was associated with our transition from a clinical-stage intranasal drug delivery company to a pre-clinical RNAi drug discovery company.

Selling, general and administrative expenses for the current quarter decreased by $2.7 million compared to the prior year quarter to $2.1 million due to our cost containment efforts.

We recorded a net restructuring charge in the first quarter of 2009 of $0.1 million, comprised of facilities related charges. Total restructuring charges were $1.9 million for the prior year quarter primarily comprised of employee severance and related costs of approximately $1.6 million and $0.3 million in net clinical trial termination fees related to the termination of the clinical trial for intranasal PTH(1-34) for osteoporosis.

We recorded an expense of $1.0 million during the current quarter related to the change in fair value of price adjustable warrants, and a net gain on settlement of liabilities $0.7 million related to our efforts during early 2009 to restructure our outstanding liabilities, including our capital lease obligations with GE capital, severance compensation and other accounts payable.

We ended the first quarter of 2009 with approximately $7.7 million in cash and cash equivalents, including $2.2 million in restricted cash, compared to approximately $3.4 million in cash and cash equivalents, including $2.3 million in restricted cash at December 31, 2008. We received a "going concern" opinion from KPMG, LLP, our independent registered accountants, in our 10-K for the 2008 fiscal year.

As previously disclosed, the Company received a Staff Determination from The NASDAQ Stock Market arising out of its non-compliance with NASDAQ Marketplace Rule 3340(a)(3), which requires a minimum of $10 million in stockholders' equity for continued listing on the NASDAQ Global Market. MDRNA presented its plan to regain compliance before the NASDAQ Listing Qualifications Panel on April 23, 2009, and is currently waiting for the Panel's response, which is expected by the end of May 2009.

FIRST QUARTER AND RECENT CORPORATE ACCOMPLISHMENTS

Strengthened Management Team and Scientific Leadership



-- Hired Barry Polisky, Ph.D., as Chief Scientific Officer. Dr. Polisky
previously served as Research Vice President at Merck & Co. and Chief
Scientific Officer at Sirna Therapeutics where he led the research and
development of RNAi-based therapeutics.
Validated RNAi Drug Discovery Platform through multiple Pharma Licensing Deals



-- Entered into a worldwide, non-exclusive sublicense agreement with
Roche for MDRNA's siRNA constructs and chemistry platform;

-- Entered into a worldwide, non-exclusive licensing agreement with
Novartis for MDRNA's liposomal technology platform for siRNA delivery.
Advanced the RNAi Drug Discovery Platform and RNAi Pipeline



-- Reported positive in vivo data on the Company's proprietary RNAi drug
discovery engine at multiple international meetings and conferences.
The Company reported:

-- Systemically delivered meroduplex siRNAs were: (1) well tolerated;
(2) effective against multiple liver targets when delivered
systemically, and (3) inhibited tumor growth when applied topically
for bladder cancer. Keystone Symposia's RNAi, MicroRNA, and Non-
coding RNA Meeting;

-- Positive data demonstrating a dose response, which resulted in up
to 90% knockdown of ApoB message in a rodent model using UsiRNAs
targeting multiple metabolic targets. Informa Life Sciences TIDES
Oligonucleotide and Peptide, Research, Technology and Product
Development Conference.

-- Refocused the Company's pipeline efforts on a single indication -
hepatocellular carcinoma (liver cancer) - to maximize the use of
capital and increase the potential success of pre-clinical studies and
early stage human clinical trials.
Restructured Key Elements of the Company



-- Eliminated rent obligations from January 2009 until July 2010 on the
Company's excess facility in Bothell, Washington through a previously
disclosed lease amendment;

-- Significantly reduced previously disclosed employee-related cash
severance payments for both a one-time cash payment due in June 2009 as
well as continuing severance payments through September 2009;

-- Significantly reduced the Company's ongoing monthly payments to
General Electric Capital Corporation on leased equipment and leasehold
improvements by restructuring the debt into a Loan and Security Agreement;

-- Our restructuring, renegotiation and cost containment efforts will
result in cash utilization of approximately $5.5 million beginning in the
second quarter of 2009, a greater than 25% reduction compared to the fourth
quarter of 2008.
Monetized Legacy Nasal Assets



-- Sold the Company's manufacturing facilities in Hauppauge, New York as
well as the Company's Abbreviated New Drug Application (ANDA) for generic
calcitonin-salmon nasal spray to Par Pharmaceuticals. Under the terms of
the Agreement, MDRNA received upfront cash and will receive profit sharing
on commercial sales of calcitonin. In addition, Par assumed MDRNA's supply
and manufacturing obligations as well as all operating costs associated
with the facilities;

-- Received an accelerated $1.0 million milestone payment from Amylin
Pharmaceuticals for advancement of the intranasal exenatide program by
amending a 2006 Development and Licensing Agreement. Under terms of the
amended agreement, MDRNA could receive up to an additional $79 million in
future milestones and royalties;

-- Engaged Adjuvant Global Advisors, LLC to identify potential licensing
opportunities for MDRNA's intranasal delivery clinical programs in Asia and
Europe.
Conference Call and Webcast Information

Management will host a conference call to review financial results for the quarter ended March 31, 2009 and recent business developments. The call is scheduled for Friday, May 15, 2009, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). To participate in the live conference call, U.S. residents should dial 866-761-0748 and international callers should dial 617-614-2706. The participant passcode for the live conference call is 95089155. To access the 24-hour telephone replay, U.S. residents should dial 888-286-8010 and international callers should dial 617-801-6888. The participant passcode for the replay is 40891910. Alternatively, to access the live audio webcast for this conference call, please go to MDRNA's Web site at http://www.mdrnainc.com approximately 15 minutes prior to the conference call in order to register and download any necessary software. A replay of the webcast will be available for 30 days following the event.

[jkids210]

MBRK- The company is meeting the sales forecast for its Moxatag launch.

John Thievon

Thank you, Faith and good morning everyone. Welcome to our call. The first quarter of 2009 was a productive one for MiddleBrook as we launched MOXATAG to trade and prepare for it's professional launch. We launched MOXATAG to healthcare professionals nationwide on March 16, 2009, while it is still very early in the launch there, indicators that we were making very good progress.

First I will run through some of the numbers and then I will share some of our findings in the field. For the first quarter of 2009, we produced revenue of $9 million, 7.5 million of which was from MOXATAG. As you can see from the net sales for MOXATAG we received solid support from our trade customers. Approximately 20,000 retail pharmacies participated in our order ship program to place a bottle of MOXATAG on the shelf in those pharmacies prior to professional promotion. This does not include pharmacies ordering independently of order ship programs.

And now that we have 300 sales reps and manager detailing healthcare professionals nationwide and driving prescriptions to pharmacies we expect distribution to increase. Keep in mind in accordance to IMS health about 40% of the annual prescription for strep throat are filled April through September. So, it’s a great time for our field force to be building awareness among healthcare professionals across the country and working to generate prescriptions for MOXATAG.

Our sales territories are align to maximize MOXATAG's market potential and our 271 sales reps and 30 district managers are detailing the physicians responsible for just over 40% of the oral solid respiratory antibiotic market for strep throat. According to IMS health national prescription audit weekly data approximately 3500 MOXATAG prescriptions have been filled as of April 24th was more than one quarter of those prescriptions filled in just one week the week ending April 24th.

This is inline with our expectations and we expect it to be a couple more months before MOXATAG prescriptions accelerate to significant levels on a weekly basis. We believe that the week over week gains we are seeing on the prescription numbers which averaged out to about 30% of the week or a positive sign. We also monitored the number of physicians writing MOXATAG and we know that new physicians are prescribing MOXATAG every week which is also a good sign.

In addition to tracking the weekly prescription numbers through IMS and prescriber data we are monitoring our check voucher program redemption rates. You may recall that we implemented this program to provide a $15 discount of the patients co-pay. This $15 savings is available at the cash register. These check vouchers are distributed to high prescribing physicians through our field sales force. Physicians can give them, to their patient along with their MOXATAG prescription. To-date about 30% of the prescription filled for MOXATAG have been accompanied by these $15 checks. We have recognized that this program has been valuable to patients thus far and we will continue to evaluate ways to keep the cost of MOXATAG affordable for all patients.

In terms of feedback in the field, I will share a few observations. Overall, comments from physicians and pharmacists are supportive with MOXATAG and its benefits which include a lower overall dose compared to conventional aminopenicillin therapies, patient convenience and compliance. On the physician front we are seeing fairly typical results in terms of rate of adoption.

In our experience it takes six or more details for a physician to change their prescribing habits and our high prescribing physicians are on about three week call cycle. So, we are just getting in front of these physicians for the second time in the last week or so. Of course, you will always have some early adopters and some that are more resistant to change.

Doctors have been writing amoxicillin for year's, so that’s a strong habit to overcome and we need to continue to deliver a solid sales message to remind doctors of MOXATAG’s significant advantages over the two to four times a day of amoxicillin. Accordingly, we are monitoring feedback very closely seeking out opportunities to accelerate our prescription results. While many pharmacists are on-board and fill 3500 prescription pharmacists represent an opportunity for us to provide education on MOXATAG’s benefits and availability.

In some cases, pharmacies called the physicians to say that the pharmacy doesn’t have MOXATAG on their show and would like the doctor to switch to a amoxicillin. Our sales reps are working diligently to resolve this issue by working with physicians office staff to ensure that the prescription is still with MOXATAG as you know there were no AB rated generic equipments in MOXATAG.

We are seeing that in some instances, the pharmacies actually have MOXATAG on the shelf but wasn’t aware that they had it. Keep in mind that a high volume pharmacy might have 10 to 15 pharmacists that work in the store on different shifts, so we need to make sure that we continue to call in the same pharmacist to increase pharmacist awareness of MOXATAG. Accordingly, our reps have increased the pharmacy calls. We are also seeing the pharmacies do not affect [ph] the MOXATAG on their shows and we are working to point out the benefits of stocking it and letting them know that the doctors are prescribing MOXATAG and will continue to do so, so they should bring in a bottle immediately.

One bottle as you may recall contains 30 tablets which equates to three prescriptions. It is important to know that pharmacies can get a bottle of MOXATAG within 24 hours. Our marketing, trade, managed care and sales management teams are working together to provide our sales reps everything they need to continue our progress and address any issues that reps are facing in the field.

Before I move on to discussing our sporting the work of our field force, I will say that overall feedback from pharmacist and physicians in the field is positive and most value the benefit of MOXATAG. We are supported in the efforts of our national field sales force with the national wide marketing campaign and raising awareness of MOXATAG among our targeted healthcare professionals and in trade and manage care. Our advertising campaign and professional publications will reach about 90% of all primary care physicians and 73% of pharmacist at least once a month during 2009. Our direct mail and email campaign that physicians, pharmacist and managed care executives will further raise awareness for MOXATAG.

As recently announced we have also launched moxatag.com a comprehensive online resource for information about MOXATAG for patients, physicians and pharmacists. And we plan to have strong attendance at medical and other professions meetings at the national and regional levels.

On the managed care coverage front, I am pleased to report that MOXATAG is widely available through managed care providers resulting in access to roughly 297 million lives. Well that number may include some duplication, we have achieved coverage for approximately 92% of all covered commercial lives in the US a territory status for both pharmacy benefit managers and managed care organizations.

MOXATAG is currently covered in third tier with their prior authorization on only about 1% of all commercial lives covered. MOXATAG is also apparently covered by medicated 46 states. We will continue working to expand our managed care and Medicaid coverage and we expect our coverage to increase overtime. We have also discovered that there are significant regional plans with co-pays from MOXATAG between $6 and $20 making MOXATAG very attractive relative to price in different parts of the country.

KEFLEX remains an important element of our overall commercial strategy and we are starting to see a flattening of the KEFLEX 750 prescriptions declined and our goal is to increase these prescriptions over time. Our reps are detailing and sampling KEFLEX 750 in the second position and we believe we will deliver stronger KEFLEX 750 messages as our reps established better relationships and have more time in front of the physicians.

And on the business development front we are continuing to review opportunities both on in licensing and co-promotion fronts. That said everything is secondary to the success of MOXATAG which remains our primary focus.

With that I will now turn the call over to Dave for review of our financial results and our business outlook.

Dave Becker

Thanks, John, and good morning to everyone. For the first quarter of 2009, our total net revenues were $9 million compared to $2.4 million for the same quarter last year. The increase is driven by initial trade stocking orders related to the MOXATAG launch, which total $7.5 million. With respect to the prescription data for the 2009 first quarter which consisted basically of the last two weeks of March total MOXATAG prescriptions were about 650.

Net sales of our KEFLEX products total $1.5 million for the first quarter a $900,000 decrease or 37% decline when compared to the 2008 first quarter results. With respect to KEFLEX prescription data for the 2009 first quarter, total prescriptions were about 46,200 compared to 74,500 for the same quarter last year.

This 38% decline is primarily due to the decision to decrease the size of the contract sales force, starting back in November of 2007. Today our 271-person field sales force plus our 30 district sales managers are deployed within territories designed to maximize MOXATAG market potential. Its also important to remember that KEFLEX is now in secondary detail position behind MOXATAG.

At this point we have begun to notice of flattening out of the decline in the number of KEFLEX prescriptions and expect to be growing those prescriptions in the months to come. Gross margin on sales was $8.2 million or 91.6% of net sales for the 2009 first quarter.

During the prior year quarter the gross margin was $1.8 million or 74% of net sales and included $279,000 charge for obsolete inventory. The improvement in gross margin percentage reflects the higher overall gross margin rate on MOXATAG as compared to our KEFLEX products.

Research and development expenses were $1.9 million for the 2009 first quarter, compared to $3.7 million for the same quarter last year. The decrease in R&D expenses over the prior year quarter is primarily driven by the reduction in facility and personnel-related expenses. You will recall that in previous quarters, we recorded significant charges related to the unused space of our Maryland facilities as well as equipment sales. As a result, we have lower overall expenses in current quarters.

Selling, general and administrative expenses for the 2009 first quarter was $16.5 million versus 4.8 million in the prior year quarter. The $11.7 million increase in SG&A expense over the prior year quarter primarily relates to the hiring, training and the deployment of our field sales force, MOXATAG marketing program related to the launch including position samples as well as increases in stock-based compensation.

Net interest income for the 2009 first quarter totaled approximately $256,000 versus approximately $125,000 during the same quarter last year. The increase in investment income is the result of higher invested cash balances offset by lower investment yields.

The final result is a net loss for the 2009 first quarter of $10 million or $0.12 per common share. This compares to a net loss of $13.8 million or $0.26 per common share during the prior year quarter. As you know, the September 2008 EGI financing resulted in the issuance of 30.3 million new common shares. And such shares were outstanding for the entire first quarter. In the prior year first quarter, there were approximately 53.3 million shares outstanding.

Now, let's move on to the balance sheet and here you will note several major changes when compared to the quarter ended December 31st of 2008.

We started the first quarter with combined cash and marketable securities balance of $74.7 million and ended with $55.4 million at March 31st of 2009. The decrease is due primarily to the increase in selling, general and administrative expenses, but it's important to note that because of the MOXATAG launch, our accounts receivables balance increased from $426,000 at December 31, 2008 to $9.5 million at March 31, 2009.

As it is typical in the pharmaceutical industry, we extended payment terms from 30 days to 90 days on initial launch orders. Therefore, we anticipate collection on these initial orders to occur during the second quarter.

Our inventories totaled $2.4 million at March 31 2009, resulting in a $2 million increase over the December 31, 2008 balance. As you would expect, our MOXATAG inventories increased due to the commercial launch of the product.

With respect to KEFLEX and as previously disclosed, we would notify by our supplier that they would be shutting down operations by the end of January of 2009. This resulted in us making a one-time order of KEFLEX inventory to ensure sufficient quantities to meet future sales demand for at least the next 18 months. We physically received that inventory during the first quarter, yet we are allowed to pay for that inventory in quarterly installments throughout 2009. We are now in the process of evaluating another contract manufacture to meet our future KEFLEX sales demand.

Our net property, plant and equipment balance was $8.6 million at March 31, 2009 compared to $4.2 million at December 31, 2008. A $4.4 million increase is driven by our automobile fleet leases for our sales force and sales managers. We are required to account for our fleet leases as capital leases and as such the present value of the lease payments must be set up as an asset with an offsetting obligation in current and long-term liabilities.

In addition, to the fleet lease liability our balances of accrued expenses and other current liabilities increased as a result of accruals for sales related liabilities such as product returns and co-pay check redemptions.

That concludes my review of the first quarter financial results. And at this point I will provide our business outlook for 2009.

As I mentioned we ended the first quarter with approximately $55.4 million in cash and marketable securities. And as a reminder our accounts receivable balance at March 31, 2009 totaled $9.5 million. As previously disclosed we expect our 2009 combined net sales for MOXATAG and KEFLEX to be in excess of $40 million. This assumes continual week-over-week growth of MOXATAG prescriptions and no generic approval and launch of an equivalent to our KEFLEX 750 milligram product.

With respect to prescription volumes we continue to expect that more than 50% of the MOXATAG prescriptions will be filled during the calendar fourth quarter of 2009. This is due to partly to seasonality but importantly the amount of time involved in changing prescriber habits. With that in mind we believe that our second quarter net sales will be under $2 million and pre-dominantly comprise of KEFLEX sales as sufficient levels of MOXATAG inventory are now in the channel and it will take sometime for those levels to be reduced to prescription fall through.

At $190,000 per representative, our field sales force is expected to cost about $51 million on an annualized basis. That's a fully burden number which includes all expenses incurred in the field as well as the cost of our district sales management and physician samples. With a significant investment in our sales force our targeted marketing campaign, product development in general and administrative expenses, we currently estimate that our total operating expenses will range between $93 million and $100 million for 2009. And keep in mind that, that includes approximately $5 million of non-cash expenses for stock options, depreciation and amortization.

Assuming FDA agreement with our clinical protocol, our current product development plan suggest that we will spend sufficient enough to advance KEFLEX process project to be prepared for patient enrolment into Phase III clinical trials during 2010. Future spending on this program is dependent upon the useful launch of MOXATAG and adequate financial resources.

And finally our current plan suggests that, if we hit our targets we could achieve operating profitability sometime in 2010.

That concludes our 2009 business outlook and at this point I will open the call up for questions.

[taraniterror]

UDHC kicks butt !!! LOL ~ Is it still trading ?

[jkids210]

Anyone have any opinioins on MBRK?

[taraniterror]

Hows UTSI doing ?

[I Love Roth Iras]

Look for NEOL as a long term play.

[Insane_Vester]

I found some more that are beginning to form the BB Boggie.

NEOM (CMF Preesure hi Accumulaing)

CHDO

SWVC (Could xplode with expecting news)

[Soul Washer]

Good call, it may continue up some..
did you notice how there was a Upper BB break with RSI & MFI crossed the 50 .
That is the boogie signal.

[Insane_Vester]

I like USSE ready to go!

[Soul Washer]

The more I look at this chart the more I like it...BB not as tight as I like, But it is at the bottom so could be setting up for a rebound. I would wait for a few positive days at the close before I would buy.

[Insane_Vester]

Soul, Check out GBDX

[Soul Washer]

UTYW!!!! Get ready for the mother of all runs!!! WHOOP!

[Soul Washer]

HTLJ up over 150% since my call in July!

[Soul Washer]

MCET up 300% on 10-10-07! Soul Washer called it on 9-12.
Sorry for late update.. been on vacation.

[The Real Titan]

I sold out at .035, but it still looks to have some gas in it. It wasn't a Top Gun play exactly, it was a personal play. If its a Top Gun Play, you'll see me call it "Top Gun Buy's XXX @ XX.XX

Either way, its was a good fast hit for a few bucks.

I took it and got into RGBI at .076, AMHD at .0011 & PHGI at .0060.

I still think RGBI is enterable, AMHD looks set to breakout & PHGI is a regular FGFC...lmao On 20 September they PR'd the following: Perihelion Global Reduces Authorized Shares to 325 Million With Delaware Secretary of State; Provides Share Structure Updates.

But whats it do since then? It goes down...lmao However, IMO its reached a point of saturation, with all the indicators ready for a bounce. We shall see...lol

[I Love Roth Iras]

NWGN @.0325 - top gun play - ride it!

[taraniterror]

UTSI another big day !

[The Real Titan]

What did you guy's get duped on??? Thats why I treat them ALL as if they were scams...lol

[jkids210]

yep, we were.

[I Love Roth Iras]

what's up kids? looks like Andre' has covered his bases with the latest press release. We were duped, shame on us.

[taraniterror]

UTSI -Up 15% on News ,contract in India !

[taraniterror]

Looks like its bottomed - Watch list for Monday - thanks.

[jkids210]

Hi everyone. What are your thoughts on DNAG?

[taraniterror]

I know !

[The Real Titan]

ROFLMAO... that's just sad.

[taraniterror]

awyi - PLEASE BUY

[taraniterror]

Hey Roth - SINCE YOUR SO BUSY LATELY AND DON'T HAVE THE TIME TO WATCH THESE OTC/BB/PINKIES day after day - I threw in some long term winners from the BIG BOARDS ! We might need to change the name of the board though , to - LONG TERM PLAYS - LOL - Let the money work for you , so you don't have to !!!! Take care --

[Soul Washer]

Look for ONSC, IMDS, and MCET for breakout!

ONSC @ .41
MCET @ .048
IMDS @ .073
GLTA!

[taraniterror]

HZO - Great company ! 52 week low. Play for the long term. Double up in a year.

[december]

Reno Gold Corp. Announces Expansion of Exploration Opportunities With Western Recon


2007-09-11 08:31 ET - News Release

VAUGHAN, ON -- (MARKET WIRE) -- 09/11/07


Reno Gold Corp. (PINKSHEETS: RNGG) is pleased to announce that it has now completed negotiations with Western Recon & Mineral Exploration Inc. The agreement was negotiated between Reno Gold Corp. and Western Recon & Mineral Exploration Inc. and will be finalized before the expected signing date of September 30th, 2007. The agreement will involve identifying properties that will be included in the Reno Gold Corp. inventory of properties. Reno and Western Recon & Mineral Exploration Inc. will work together to set timetables for any exploration programs for all the properties acquired under this agreement. The relationship between Reno Gold Corp. and Western Recon & Mineral Exploration Inc. is a key component of Reno's business strategy to inventory the best possible mineral exploration properties available in Nevada.

Talal Chehab, Secretary Treasurer of Reno Gold Corp., explained, "We are delighted to have concluded this agreement with Western Recon. Both our teams are committed to the same vision. I expect we will be able to inventory some very interesting properties and be able to deliver some solid blue sky potential for Reno Gold shareholders."

About Reno Gold Corp.:

The company was formed as a precious metals mining, exploration and Development Company in June 2004. Reno Gold Corp. is managed by an experienced team with a successful track record in exploration and mine development. The goal of the company is to maximize shareholder value by identifying the highest yielding ore bodies available in the State of Nevada. Nevada boasts an enviable history of hosting some of the world's largest ore bodies and areas including the world famous Carlin Trend. Numerous large exploration companies operate in Nevada including Newmont Mining, Barrick Gold and Glamis Gold. Any additional properties acquired in Nevada will compliment Reno Gold Corp.'s 60% interest in the Good Hope Property which is in year two of a three year exploration program. The Good Hope Property is located in Elko County, Nevada. Nevada accounts for most of America's gold production. The 2000 acre property is adjacent to Jerritt Canyon Mines which has produced over 12,000,000 ounces of gold to date.

This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to those detailed from time to time in the Company's filings with the Securities and Exchange Commission.


Contact:
Reno Gold Corp.
Investor Relations
416-960-4144

[The Real Titan]

Your gonna have to stop by and check out the NEW forum...lol We just finished installing it and having the old one converted into the new, so we wouldn't lose any content or user data. It should be up later on tonight, ready for tomorrows trading day.

[I Love Roth Iras]

ugly market, I have been choosing not to watch.

[The Real Titan]

VNECQ is currently down 40%, but looking probable for a strong run into the close. I'm in at .0050 and .0070, so I'll be looking for a push here soon.

[The Real Titan]

JPEI and RNWR... In both now, looking to see them gap in the morning, but who knows

[I Love Roth Iras]

PM: rats! wish I would have read your messages yesterday, I could have made some $$$. Been pretty busy the last couple weeks.

[Soul Washer]

UTYW 10qsb


Results of Operations

Three-month period ended June 30, 2007 and 2006:

Sales and Cost of Goods Sold

Sales for the three-month period ended June 30, 2007 were $2,621,630, an increase of 31.19% or $623,233, from $1,998,397 for the three-month period ended June 30, 2006. In both our historical product lines and new product lines obtained through acquisitions we have seen a greater diversification in our customer base and geographical areas where the company is now selling its expanded product offerings.

Cost of goods sold during the three-month period ended June 30, 2007 was $2,087,647 resulting in a gross margin of $533,983 or 20.37% of sales, compared to $1,597,679 for the three-month period ended June 30, 2006 resulting in a gross margin of $400,718 or 20.05% of sales.

The increase in gross margin is largely attributed to:

-

Increase in sales, resulting in increased component requirements and the company has been able to negotiate better pricing from its outsourced manufacturer due to the higher purchased volume;

-

Efficiencies and cost savings have been obtained by centralizing our manufacturing and procurement largely with one outsourced manufacturer;

-

Efficiencies and cost savings have been obtained by centralizing our final testing of products in our China facility where the company has also been able to benefit from lower payroll costs.



http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=5382846

[taraniterror]

Had my trigger finger on UTSI all day but didn't pull - I'M A IDIOT !!! Opened $2.65 - Spiked to $4.14 at end of day.

XRM performed pretty well on a down day.

UCOI had order in at .001 - bid dropped down to .001 but no sellers there. Always tomorrow -

SNTS had a great day - DROPPED .23 CENTS AFTER HOURS, NOT SURE WHY OR ON HOW MUCH VOLUME - I had an order in at $1.85, the way the day started - I FIGURED IT WOULD HAVE GOT FILLED - Nice rebound.

UTSI STILL BUGS THE CRAP OUT OF ME ! Was looking at GNTA and MOVI instead. Live and learn. Picked up 6k shares of GNTA @ .805.Closed at .86 and then dropped to .72 after hours - Uggg..

[The Real Titan]

OUch... well I hope your making it back by flipping it.

Good Luck!!!

[undervalue]

Thank you, I lost more than 40K with that...